Bayer finalized a €3 billion capital agreement with investment firms Apollo and KKR. This transaction follows an initial announcement made on July 10.
Apollo and KKR acquired a minority, non-controlling stake in a new entity holding Bayer’s long-acting reversible contraceptives (LARC) business. Bayer retains a majority stake and full operational control.
The LARC portfolio includes the Mirena and Kyleena brands. This business remains a core component of Bayer’s pharmaceuticals division and stays fully consolidated in financial reports.
Management designed the strategic financing solution to enhance the company’s capital structure. The move provides financial flexibility to manage upcoming bond maturities and ongoing litigation costs.